Patent ID: 6828318
Filing Date: 2004-12-07
Classification: A61K,A61P,C07C,C07D

Abstract:
A method of treatment of a condition generally associated with abnormalities in glutamatergic transmission, comprising administering, to a patient in need of such treatment, a pharmaceutically effective dose of a compound of formula (1): whereinR1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl, aryl and non-aromatic heterocyclic groups, or each of one or more pair(s) of the substituent groups R1 to R6 may together form a 3, 4, 5, 6, 7 or 8-membered ring containing 0, 1 or 2 heteroatom(s); R7 is selected from alkyl, aryl and non-aromatic heterocyclic groups; and R8 is selected from hydrogen, halogen, alkyl, aryl and non-aromatic heterocyclic groups; or a pharmaceutically acceptable salt or prodrug thereof.